To settle cases, billionaire family say they won't hide OxyContin profits.
Enlarge / PURDUE PHARMA, STAMFORD, Conn. - 2019/09/12: Members of P.A.I.N. (Prescription Addiction Intervention Now) and Truth Pharm staged a protest on September 12, 2019, outside Purdue Pharma headquarters in Stamford, over their recent controversial opioid settlement. (credit: Getty | Erik McGregor)
OxyContin-maker Purdue Pharma and its billionaire owners, the Sacklers, on Friday got a temporary reprieve from lingering court battles over their alleged role in fueling the opioid crisis. In exchange, they may have to be more forthcoming about what happened to all the OxyContin money.
US bankruptcy Judge Robert Drain temporarily halted state lawsuits against Purdue as well as the Sacklers—though only Purdue has filed for bankruptcy protections. In pausing the states' cases, Judge Drain cited Purdue's mounting legal expenses, which he noted is money that could otherwise go toward addressing the opioid crisis and its victims, according to The New York Times.
Purdue had sought a 180-day injunction on the state's cases, but Judge Drain's pause only lasts until November 6. In that shorter timeframe, he pushed the parties to try to talk out their differences. Those differences primarily hinge on whether the Sacklers are offering enough of their allegedly ill-gotten fortune to address the opioid crisis in thousands of lawsuits on the matter.
Read 7 remaining paragraphs | Comments
